Upfront Combo Lipid-Lowering Therapy Best for Acute Coronary Syndrome

FRIDAY, Sept. 8, 2023 -- For patients with acute coronary syndromes (ACS), an upfront combination lipid-lowering therapy is significantly better than statin monotherapy for all-cause mortality, according to a study published online Sept. 6 in the...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news